Browsing Tag
Immatics N.V.
1 post
Immatics skips interim anzu-cel analysis and adds 90 patients ahead of pivotal 2027 verdict
Immatics adds 90 patients to anzu-cel Phase 3 while its $448.2m liquidity backs a definitive 2027 melanoma readout and planned BLA.